An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
VERDICT
The label
Markdown
read at $300.14
Ligand Pharmaceuticals Incorporated holds its Markdown at $300.14.
PHPhase · the trend structure carries the Markdown label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · does not pass the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-08-06
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 1 days
Price
$300.14
Valuation
39.08 trailing · 24.98 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.98
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$300.14
39.08 P/E · 24.98 fwd
Our fair value
$304.67
2% discount
Analyst target (avg)
$345.00
+15% to current
Target low $247.00Analyst target rangeTarget high $388.00
▲ current $300.14 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$300.14
you are here
Conservative
$222.30
-26%
Analyst avg
$345.00
+15%
Our fair value
$304.67
+2%
Analyst high
$388.00
+29%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish — a quality-at-a-fair-price name rather than a deep-value one.
Revenue growth
14.10%
Profit margin
55.95%
Debt to equity
45.32
Analyst consensus
Strong Buy · 10 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✗ DOES NOT PASS
Why it fails. The problem is its revenue purity. Because both standards agree on this, it is a clear exclusion, not a borderline case.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 28.9% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 12.6% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 15.0% of assets, under the 49% limit.Pass
Revenue purity5.1% of revenue comes from non-compliant sources, over the 5% line.Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Biotech licensor offers strong margins yet no margin of safety
Picture a company that simply licenses drug formulas rather than running full clinical trials. Ligand does exactly that and posts a 56 percent profit margin with 14 percent revenue growth and 17 percent return on equity. Those numbers look solid on paper yet our fair value sits at 281.87 while the shares trade at 303.39, giving a negative margin of safety and a clear none rating on opportunity.
The business model keeps overhead low by partnering assets such as EVOMELA and KYPROLIS into approved treatments worldwide. Forward earnings sit at 26.3 times and ten analysts still carry a strong buy stance with a 310 median target. Ethical screening clears the name without issue, which removes one common reason to step aside.
Valuation risk remains the decisive factor here. A modest premium to fair value can quickly reverse in a sector where royalty streams face patent cliffs and partner concentration. The absence of any moat rating adds further uncertainty around durability. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
LGND trades on Nasdaq. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 120%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (10 analysts) rates it strong buy, with a mean price target of $272. Entered 2026-08-04 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-08-04Markup$287.54+12.5%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 120%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (10 analysts) rates it strong buy, with a mean price target of $272.
2026-07-18Markup$255.54+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 120%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (10 analysts) rates it strong buy, with a mean price target of $272.
2026-07-03Markup$255.54+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$255.54Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$220.48
+12.9%
·
$1,129
+12.9%
2 months
$204.92
+21.5%
·
$1,215
+21.5%
3 months
$211.48
+17.7%
·
$1,177
+17.7%
6 months
$183.13
+36.0%
·
$1,360
+36.0%
1 year
$113.42
+119.5%
·
$2,195
+119.5%
2 years
$79.53
+213.1%
·
$3,131
+213.1%
3 years
$73.76
+237.6%
·
$3,376
+237.6%
5 years
$77.12
+222.9%
·
$3,229
+222.9%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever LGND does next, these words stay.
Ligand Pharmaceuticals Incorporated · LGND · Markdown · $300.14
Recorded 2026-08-06 · before the outcome · scored mechanically
